Preclinical research reported that DUSP4 can enhance antitumor CD8+ T-cell function and improve CAR-T efficacy in colorectal cancer mouse models. The study frames DUSP4 as a target for strengthening immune-cell performance in solid tumor environments where therapeutic efficacy often wanes. The work is positioned as part of an effort to address a persistent limitation of cell therapies: functional exhaustion or suppression once CAR-T cells infiltrate and encounter tumor-associated immune barriers. Published results add another candidate regulatory node for combination engineering or selection strategies. While the findings are limited to animal studies, they expand the set of immune-modulating targets under evaluation for next-generation CAR-T performance optimization.